JP5599773B2 - リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体 - Google Patents

リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体 Download PDF

Info

Publication number
JP5599773B2
JP5599773B2 JP2011500282A JP2011500282A JP5599773B2 JP 5599773 B2 JP5599773 B2 JP 5599773B2 JP 2011500282 A JP2011500282 A JP 2011500282A JP 2011500282 A JP2011500282 A JP 2011500282A JP 5599773 B2 JP5599773 B2 JP 5599773B2
Authority
JP
Japan
Prior art keywords
cyclopenta
pharmaceutical composition
composition according
cells
phenylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011500282A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515384A5 (OSRAM
JP2011515384A (ja
Inventor
ヤンセン，ゲリット
ジャックマン，アン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0805035A external-priority patent/GB0805035D0/en
Priority claimed from GB0805036A external-priority patent/GB0805036D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of JP2011515384A publication Critical patent/JP2011515384A/ja
Publication of JP2011515384A5 publication Critical patent/JP2011515384A5/ja
Application granted granted Critical
Publication of JP5599773B2 publication Critical patent/JP5599773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2011500282A 2008-03-18 2009-03-13 リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体 Active JP5599773B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0805035A GB0805035D0 (en) 2008-03-18 2008-03-18 Us eof cyclopenta[G]quinazoline derivatives
GB0805036.1 2008-03-18
GB0805035.3 2008-03-18
GB0805036A GB0805036D0 (en) 2008-03-18 2008-03-18 New use of cyclopenta[g]quinazoline derivatives
PCT/GB2009/000687 WO2009115776A1 (en) 2008-03-18 2009-03-13 Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia

Publications (3)

Publication Number Publication Date
JP2011515384A JP2011515384A (ja) 2011-05-19
JP2011515384A5 JP2011515384A5 (OSRAM) 2012-05-10
JP5599773B2 true JP5599773B2 (ja) 2014-10-01

Family

ID=40599662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011500282A Active JP5599773B2 (ja) 2008-03-18 2009-03-13 リウマチ様関節炎又は急性骨髄性白血病の治療のためのシクロペンタ［ｇ］キナゾリン誘導体

Country Status (10)

Country Link
US (1) US8466111B2 (OSRAM)
EP (1) EP2293807B1 (OSRAM)
JP (1) JP5599773B2 (OSRAM)
KR (1) KR101616022B1 (OSRAM)
CN (1) CN101977620B (OSRAM)
AT (1) ATE556715T1 (OSRAM)
CA (1) CA2717954C (OSRAM)
DK (1) DK2293807T3 (OSRAM)
ES (1) ES2387334T3 (OSRAM)
WO (1) WO2009115776A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028918T2 (en) * 2010-12-22 2017-01-30 Btg Int Ltd Effective peptide couplings and their use in the synthesis and isolation of cyclopenta (G) quinazoline trinodium salt
EA201990473A1 (ru) 2016-08-12 2019-07-31 Эл.И.Эй.Эф. ХОЛДИНГС ГРУП ЭлЭлСи Полиглутамированные антифолаты и их применение
WO2018031967A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
GB201707864D0 (en) 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment
EP3749311A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
EP3749316A4 (en) 2018-02-07 2021-10-27 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF
CA3090389A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
EP3749312A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF
CN111954529A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化氨甲蝶呤及其用途
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
EP3749318A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
US11771700B2 (en) 2018-02-14 2023-10-03 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
EP3752156A4 (en) * 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
CN111936145A (zh) 2018-02-14 2020-11-13 L.E.A.F.控股集团公司 γ聚谷氨酸化氨甲蝶呤及其用途
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
WO2019169029A1 (en) * 2018-02-28 2019-09-06 Bioxiness Pharmaceuticals, Inc. Target specific chemotherapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US7297701B2 (en) * 2001-08-31 2007-11-20 Btg International Limited Anti-cancer cyclopenta [G]quinazoline compounds
WO2003020300A1 (en) * 2001-08-31 2003-03-13 Btg International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
CA2503094A1 (en) * 2002-02-27 2003-09-04 The Ohio State University Research Foundation Therapeutic methods for acute myeloid leukemia

Also Published As

Publication number Publication date
US8466111B2 (en) 2013-06-18
HK1154786A1 (en) 2012-05-04
CA2717954A1 (en) 2009-09-24
CA2717954C (en) 2019-06-04
EP2293807B1 (en) 2012-05-09
DK2293807T3 (da) 2012-07-23
KR20110002848A (ko) 2011-01-10
ATE556715T1 (de) 2012-05-15
JP2011515384A (ja) 2011-05-19
CN101977620B (zh) 2014-05-07
WO2009115776A1 (en) 2009-09-24
US20110190211A1 (en) 2011-08-04
ES2387334T3 (es) 2012-09-20
EP2293807A1 (en) 2011-03-16
CN101977620A (zh) 2011-02-16
KR101616022B1 (ko) 2016-04-28

Similar Documents

Publication Publication Date Title
EP2293807B1 (en) Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia
Van Der Heijden et al. Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients
JP6712427B2 (ja) 移植片対宿主病を処置し予防する方法
TW202216208A (zh) 抗體-藥物結合物及atr抑制劑之組合
CN111225903B (zh) 谷氨酰胺酶抑制剂疗法
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
BRPI0719109A2 (pt) Métodos para tratar doenças inflamatórias crônicas usando um antagonista de gm-csf
JP2020105181A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
KR20240014585A (ko) 악성 종양 치료용 제제 및 조성물
UA119538C2 (uk) Лікування злоякісної пухлини дигідропіразинопіразинами
JPWO2012111790A1 (ja) 化学療法剤の抗腫瘍活性増強剤
CA3218253A1 (en) Dosing regimens of peptide conjugates of topoisomerase i inhibitors
EP1420809B1 (en) Use of cyclopenta[g]quinazoline derivatives for treating cancer
US20250368617A1 (en) Novel ras inhibitors
TW202128212A (zh) 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途
US8940701B2 (en) Compounds for, and methods of, treating cancer and inhibiting invasion and metastases
HK1154786B (en) Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia
JP2018517788A (ja) リンパ腫を治療するためにベリノスタットおよびプララトレキサートを使用する組合せ療法
CN101282728A (zh) 有机化合物的组合
US20250360124A1 (en) Novel ras inhibitors
KR101351682B1 (ko) 전신 비만세포증 치료용 조성물
EA049478B1 (ru) Комбинация конъюгата антитела и лекарственного средства и ингибитора atr
WO2023242098A1 (en) Novel ras inhibitors
Laan Sensitivity to methotrexate and novel antifolates in human squamous carcinoma cell lines of the head and neck

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140715

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140813

R150 Certificate of patent or registration of utility model

Ref document number: 5599773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250